News
-
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Jaguar Health, Inc. to conduct an investor webcast on May 14, 2024, to review first-quarter financials and provide corporate updates. Company plans to file its Earnings Report on the same day -
-
PRESS RELEASE
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
Jaguar Health, Inc. establishes Investigational New Animal Drug (INAD) file with FDA for crofelemer to treat canine diarrhea. Conditional approval received for chemotherapy-induced diarrhea (CID) in dogs -
-
PRESS RELEASE
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's plant-based drug crofelemer granted Orphan Drug Designation for MVID and SBS, with proof-of-concept studies planned for 2024. Napo sponsors Elite Ped-GI Congress panel discussion on rare digestive disorders -
-
-
-
PRESS RELEASE
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis joins Jaguar Health, facilitating in-license agreement for FDA-approved Gelclair® for oral mucositis management. Collis brings 25 years of biopharmaceutical experience to Senior VP role at Jaguar. Gelclair provides pain relief for cancer patients' supportive care needs
-
Robust Intelligence Partners With Pinecone to Secure Retrieval-Augmented Generation (RAG) AI Applications
-
Boron One Announces Successful Closing of Early Warrant Exercise Incentive Program
-
Eagle Plains Announces Conditional Approval of Warrant Expiry Extension
-
Goldflare Announces Changes in Leadership
-
Gina Corena & Associates Participates in 2024 Nevada Justice Association Annual Summer Gala This Weekend
-
EQS-Adhoc: VOLKSWAGEN AKTIENGESELLSCHAFT: Volkswagen AG resolves on investment by Volkswagen of initially 1 billion USD in Rivian Automotive, Inc., and intends to establish a joint venture
-
CompuGroup Medical strengthens market position in Northern Europe with the acquisition of Norwegian Pridok
-
EQS-Adhoc: CompuGroup Medical SE & Co. KGaA: CompuGroup Medical acquires Pridok AS
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
Annual General Meeting 2024 of Meyer Burger approves all motions
-
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
-
Schneider Electric announces the reference share price and the initial conversion/exchange ratio of its new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 and the results of the repurchase of the OCEANEs
-
FREY signs new financing for €400m
-
Schneider Electric announces the success of its offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million
-
Cie du Bois Sauvage: Buy back of own shares – week from 17/06/2024 to 21/06/2024